Global Antiviral Drugs Market Trends, Forecast Report 2025-2037
Antiviral Drugs Market size is expected to increase from USD 56.69 billion to USD 95.1 billion, registering a CAGR of more than 4.2% during the forecast period, from 2025 through 2037. In the year 2025, the industry size of antiviral drugs is assessed at USD 58.55 billion.
The increasing cases of hepatitis B infection and high investment in R&D activities on antiviral drugs across the world will propel the market growth. As per the World Health Organization, about 296 million people are suffered from chronic hepatitis B infection in 2019. The growing incidence rate of infectious diseases such as herpes simplex virus, hepatitis virus, and influenza. As per the observations, between September to October 2022, nearly 5300 members tested positive for the influenza virus.
Antiviral Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Geriatric Population – The rising number of old people across the world and their rising high chances of getting viral infections is estimated to boost the antiviral drugs market growth during the forecast period. Old people are susceptible to diseases due to less immune strength which makes them more prone to any disease or infection. As per the World Health Organization, the number of people aged 60 years and above rose from 1 billion in 2020 to 1.4 billion in 2022.
- Increased Cases of COVID – 19 – The number of global COVID cases across the world in 2022 was 625,700,400 as per the estimations.
- Rising Risk of STDs Among Adults – According to the observations, over 1 million sexually transmitted diseases occur each year with an estimated more than 350 new infections.
- Growing Demand for Generic Versions – As per the IMS Health Institute, the healthcare system of the U.S saved USD 2.2 trillion between 2009 to 2019 with the use of generic drugs.
- Rising Vaccinations Against Viral Infections – The COVID-19 vaccine was administered in more than 13 billion doses until 2022.
Challenges
- Increasing Awareness About Preventive Drugs Treatment
- Presence of Generics
- Drug Resistance
Antiviral Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.2% |
|
Base Year Market Size (2024) |
USD 56.69 billion |
|
Forecast Year Market Size (2037) |
USD 95.1 billion |
|
Regional Scope |
|
Antiviral Drugs Segmentation
Drug Class - (DNA Polymerase, Reverse Transcription, Protease, Neuraminidase Inhibitors)
The reverse transcription is anticipated to hold the largest antiviral drugs market size by the end of 2037, on the back of growing diagnosis and treatment rate of HIV infection and the increasing efficiency of antiviral drugs on viral diseases. In 2021, about 29 million individuals who suffered from HIV received antiretroviral therapy.
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5,355.79, which grew from USD 3,515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in the upcoming years.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Indication |
|
|
By Type |
|
|
By Age Group |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAntiviral Drugs Industry - Regional Synopsis
The market in North America region is expected to dominate largest share by the end of 2037, on the back of growing patient base, the strong foothold of industry key players, increasing approval, and the expected commercialization of new drugs for viral diseases. In 2022, the number of COVID-19 cases increased by 8% in North America.
Companies Dominating the Antiviral Drugs Landscape
- AstraZeneca LP
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline, Plc
- Bristol Myers Squibb Company
- Abbott Laboratories
- Plough Publishing House
- Merck & Co., Inc
- Johnson & Johnson Services, Inc
- AbbVie Inc.
- Cipla Inc.
- Dr Reddy’s Laboratories Ltd.
In the News
-
Merck & Co., Inc. announced that Molnupiravir, an oral antiviral investigational medicine used to reduce the risk of hospitalization or death.
-
Johnson & Johnson Services, Inc. declared the introduction of a multi-pronged response against novel Coronavirus. This is also used to determine the coronavirus pathophysiology to help patients survive from 2019-nCoV infection.
Author Credits: Radhika Pawar
- Report ID: 473
- Published Date: Jan 17, 2025
- Report Format: PDF, PPT
